BTIG Research upgraded shares of Serina Therapeutics (NYSEAMERICAN:SER – Free Report) to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports.
Serina Therapeutics Stock Down 1.0%
Shares of NYSEAMERICAN:SER opened at $1.90 on Wednesday. The company has a quick ratio of 4.18, a current ratio of 4.18 and a debt-to-equity ratio of 0.24. The company has a market cap of $28.50 million, a PE ratio of -0.95 and a beta of 1.11. The business has a 50 day simple moving average of $1.84. Serina Therapeutics has a twelve month low of $1.22 and a twelve month high of $7.92.
Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share (EPS) for the quarter.
Serina Therapeutics Company Profile
Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.
Further Reading
- Five stocks we like better than Serina Therapeutics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Serina Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Serina Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
